SCHEMBL7342248

SCHEMBL7342248

CC(=O)N(c1ccccc1)[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 2/20 0.39
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
BLM P54132 2/20 0.37
PMP22 Q01453 2/20 0.37
ALOX15 P16050 1/20 0.37
MAPT P10636 2/20 0.36
TSHR P16473 2/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
PARP1 P09874 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7342254 1.00 ALDH1A1 (0.40) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL6464595 0.98 ALDH1A1 (0.39) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL7345170 0.98 MMP2 (0.40) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL28294340 0.88 KMT2A (0.40) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL7345167 0.87 LMNA (0.37) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL6535237 0.85 SMN1; SMN2 (0.41) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL757884 0.84 TP53 (0.48) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL29033834 0.84 ALDH1A1 (0.40) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL8429495 0.84 LMNA (0.39) ALDH1A1LMNATP53SMN1; SMN2KMT2A
SCHEMBL8429588 0.84 LMNA (0.39) ALDH1A1LMNATP53SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110088615-A Detection and quantitative mass spectrometric determination method for renal function metabolin 梅塔博隆股份有限公司 2019-08-02 CN claimed
CN-106714556-A Methods and systems for determining risk of autism spectrum disorders 美国控股实验室公司 2017-05-24 CN claimed
CN-105209909-A Biomarkers associated with renal function and methods of use thereof METABOLON INC 2015-12-30 CN claimed
EP-3616721-B1 BLOOD PURIFICATION BY ALKALINIZING AGENT UNIV TOHOKU (JP) 2024-12-04 EP disclosed
CN-113970606-B Metabolic markers for diagnosing attention deficit hyperactivity disorder syndrome in urine of children 首都医科大学附属北京儿童医院 2022-06-14 CN disclosed
CN-113970606-A Metabolic markers for diagnosing attention deficit hyperactivity disorder syndrome in urine of children 首都医科大学附属北京儿童医院 2022-01-25 CN disclosed
US-20210389331-A1 Method for Diagnosing Intermittent Claudication and Chronic Limb-Threatening Ischemia UNIV MCMASTER (CA) 2021-12-16 US disclosed
EP-3918603-A1 PREDICTING BLOOD METABOLITES Yeda Research and Development Co. Ltd (IL) 2021-12-08 EP disclosed
US-20210315816-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-14 US disclosed
WO-2021113989-A1 METHOD OF DIAGNOSING AND TREATMENT MONITORING OF CROHN'S DISEASE AND ULCERATIVE COLITIS MCMASTER UNIVERSITY (CA) 2021-06-17 WO disclosed
US-20210121426-A1 BLOOD PURIFICATION BY ALKALINIZING AGENT TOHOKU UNIVERSITY (JP) 2021-04-29 US disclosed
CN-101272763-A Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate NAVINTA LLC (US) 2008-09-24 CN disclosed
CN-1343489-A Novel percutaneous absorption dosage form of medicine for resisting cancer and inhibiting cell hyperproliferation or poor differentiation ZHONG YILIN (CN) 2002-04-10 CN disclosed
EP-0500905-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS. BURZYNSKI STANISLAW R (US) 1992-09-02 EP disclosed
WO-1992004027-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS BURZYNSKI STANISLAW R (US) 1992-03-19 WO disclosed
EP-0069232-B1 PHARMACEUTICAL COMPOSITION COMPRISING PHENYL ACETYL GLUTAMINE,A COMBINATION OF THIS COMPOUND WITH PHENYLACETIC ACID OR 3-(PHENYLACETYLAMINO)PIPERIDINE-2,6-DIONE,A PROCESS FOR ISOLATING THE LATTER FROM URINE AND A PROCESS FOR THE SYNTHESIS OF 3-(PHENYLACETYLAMINO)PIPERIDINE-2,6-DIONE BURZYNSKI, Stanislaw R. (US) 1986-10-29 EP disclosed
US-4559325-A ANTITUMOR AGENTS BURZYNSKI STANISLAW R (US) 1985-12-17 US disclosed
US-4558057-A URINE EXTRACTS BURZYNSKI STANISLAW R (US) 1985-12-10 US disclosed
US-4470970-A ANTITUMOR AND-CARCINOGENIC AGENT EXTRACTED FROM URINE BURZYNSKI STANISLAW R 1984-09-11 US disclosed
EP-0069232-A2 Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione BURZYNSKI, Stanislaw R. (US) 1983-01-12 EP disclosed